Startseite Kongressberichte 2019 Annual Meeting of the American Society of Clinical Oncology 2019 Breast Cancer Oral & Poster Presentations

Choice of Oral & Poster Presentations

Peter Schmid, Sylvia Adams, Hope S. Rugo, Andreas Schneeweiss, et al.

IMpassion130: updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) + nab-paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC).

Conclusions: The 2nd IMpassion130 interim OS analysis was consistent with the 1st analysis, confirming clinically meaningful OS benefit with atezo + nP in previously untreated PD-L1+ mTNBC. Clinical trial information: NCT02425891

  Atezo + nP Placebo + nP
ITT population, events/pts, n/n (%) 255/451 (57%) 279/451 (62%)
HR (95% CI); log-rank P 0.86 (0.72, 1.02); 0.078a ―
Median OS (95% CI), mo 21.0 (19.0, 22.6) 18.7 (16.9, 20.3)
2-year OS (95% CI), % 42 (37, 47) 39 (34, 44)
Median follow-up duration, mo 18.5 17.5
PD-L1+ population,b events/pts, n/n (%) 94/185 (51%) 110/184 (60%)
HR (95% CI) 0.71 (0.54, 0.93) ―
Median OS (95% CI), mo 25.0 (19.6, 30.7) 18.0 (13.6, 20.1)
2-year OS (95% CI), % 51 (43, 59) 37 (29, 45)

HRs estimated per stratified Cox model. a Not significant. b PD-L1 on IC ≥ 1% (VENTANA SP142 IHC assay).